NextCure NXTC 深 沪

美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级

今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元

05-12 12:36

NextCure Q1 EPS $(1.87) Beats $(2.12) Estimate

NextCure (NASDAQ:NXTC) reported quarterly losses of $(1.87) per share which beat the analyst consensus estimate of $(2.12) by 11.79 percent. This is a 60.21 percent increase over losses of $(4.70) per share from the same

05-08 04:33

NextCure Provides Business Update and Reports First Quarter 2026 Financial Results

NextCure, a biopharmaceutical company, announced updates on its SIM0505 (CDH6 ADC) and LNCB74 (B7-H4 ADC) programs. SIM0505 received FDA Fast Track designation for platinum-resistant ovarian cancer (PROC) and will present Phase 1 data at ASCO 2026. Dose optimization studies have begun, with plans to expand trial sites in the U.S., Canada, and Europe. LNCB74's Phase 1 trial is ongoing, with updates expected in the second half of 2026. The company ...

05-07 20:05

NextCure And Simcere Zaiming Announce Phase 1 Data For SIM0505 In Treatment Of Solid Tumors Will Be Presented At ASCO 2026

NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co.,

04-21 22:18

先声再明SIM0505获美国FDA快速通道认定 用于治疗铂耐药卵巢癌

2026年4月8日，先声再明宣布，靶向CDH6的抗体药物偶联物（ADC）在研新药SIM0505，获得美国食品药品监督管理局（FDA）授予的快速通道认定，用于治疗...

04-08 09:45

NextCure's SIM0505 Receives FDA Fast Track For Platinum-Resistant Ovarian Cancer, Phase 1 Data To Be Presented At ASCO 2026

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SIM0505 for the treatment of women with platinum resistant ovarian cancer (PROC) Phase 1 data for SIM0505 to be presented at ASCO

04-07 20:14

NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026

NextCure and Simcere Zaiming announced the acceptance of an abstract for SIM0505, an investigational ADC targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor payload, at the 2026 ASCO meeting in Chicago. The Phase 1 study (NCT06792552) evaluates SIM0505 in advanced solid tumors, focusing on platinum-resistant ovarian cancer. NextCure holds global rights for SIM0505, excluding China, Hong Kong, Macau, and Taiwan, managed by Sim...

03-31 20:05

NextCure GAAP EPS of -$19.65

NextCure press release (NXTC): FY GAAP EPS of -$19.65. Cash, cash equivalents, and marketable securities as of December 31, 2025 were $41.8 million as compared to $68.6 million as of December 31, 2024...

03-06 15:47

NextCure Q4 EPS $(0.81) Beats $(2.42) Estimate

NextCure (NASDAQ:NXTC) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(2.42) by 66.49 percent. This is a 83.54 percent increase over losses of $(4.92) per share from the same

03-06 05:14

NextCure Provides Business Update and Reports Full Year 2025 Financial Results

03-05 21:05